
Neoleukin Therapeutics Net Income | NLTX
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Neoleukin Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -90.4 M | -75.1 M | -36.3 M | -55.2 M | -60.7 M | -33.3 M | -69.4 M | -31.6 M | -50.2 M | -37 M | -21.9 M | -24 M | -8.73 M | -7.71 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -7.71 M | -90.4 M | -43 M |
Quarterly Net Income Neoleukin Therapeutics
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -29 M | -34.5 M | -30.9 M | -24.7 M | -21 M | -22 M | -22.6 M | -19.5 M | -20.2 M | -18.5 M | -16.9 M | 2.38 M | -14.6 M | -11.9 M | -12.3 M | -11.1 M | -13.1 M | -15.7 M | -15.4 M | -15.2 M | -15.4 M | -15.1 M | -15 M | -12.6 M | -2.25 M | -9.75 M | -8.64 M | -8.1 M | -59.1 M | -1 K | -2.21 M | - | -15 M | 2.92 M | -14.6 M | -16.3 M | -11.8 M | -13.8 M | -8.32 M | -11.2 M | -8.15 M | -10.9 M | -6.71 M | -5.66 M | -5.04 M | -4.75 M | -6.41 M | -8.09 M | -6.28 M | -5.42 M | -4.02 M | - | -3.37 M | -812 K | -1.01 M | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.92 M | -59.1 M | -12.8 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Drug manufacturers industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Lannett Company
LCI
|
-232 M | - | 1.15 % | $ 7.11 M | ||
|
Recro Pharma
REPH
|
-13.3 M | - | -4.76 % | $ 65.3 M | ||
|
Evoke Pharma
EVOK
|
-5.35 M | - | - | $ 36.6 M | ||
|
Endo International plc
ENDP
|
-2.45 B | - | - | $ 28.9 M | ||
|
Aerie Pharmaceuticals
AERI
|
-74.8 M | - | - | $ 754 M | ||
|
Alimera Sciences
ALIM
|
-20.1 M | - | - | $ 142 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
-35 M | - | - | $ 55.5 M | ||
|
Radius Health
RDUS
|
-70.2 M | - | - | $ 1.42 B | ||
|
Avadel Pharmaceuticals plc
AVDL
|
-48.8 M | - | - | $ 2.06 B | ||
|
PetIQ
PETQ
|
2.13 M | - | 1.64 % | $ 400 M | ||
|
Solid Biosciences
SLDB
|
-174 M | $ 6.35 | 1.85 % | $ 556 M | ||
|
TherapeuticsMD
TXMD
|
-569 K | $ 1.82 | -4.71 % | $ 21.1 M | ||
|
Agile Therapeutics
AGRX
|
-14.5 M | - | 10.11 % | $ 58.2 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
-26.5 M | - | 0.86 % | $ 117 M | ||
|
cbdMD
YCBD
|
-2.04 M | $ 0.37 | 1.62 % | $ 1.49 M | ||
|
Aurora Cannabis
ACB
|
1.59 M | $ 4.41 | -2.43 % | $ 242 M | ||
|
Eagle Pharmaceuticals
EGRX
|
35.6 M | - | -39.89 % | $ 27.7 M | ||
|
Tricida
TCDA
|
-177 M | - | - | $ 3.25 M | ||
|
DURECT Corporation
DRRX
|
-8.32 M | - | - | $ 50.1 M | ||
|
Athenex
ATNX
|
-103 M | - | -23.39 % | $ 1.76 M | ||
|
PLx Pharma
PLXP
|
-46.1 M | - | -27.8 % | $ 2.56 M | ||
|
Tilray
TLRY
|
-121 M | $ 2.25 | -4.06 % | $ 252 M | ||
|
Catalent
CTLT
|
-1.04 B | - | - | $ 11.5 B | ||
|
Relmada Therapeutics
RLMD
|
-57.4 M | $ 2.86 | -4.98 % | $ 113 M | ||
|
OptiNose
OPTN
|
-21.5 M | - | - | $ 1.08 B | ||
|
Canopy Growth Corporation
CGC
|
-263 M | $ 0.5 | -5.01 % | $ 149 M | ||
|
China Pharma Holdings
CPHI
|
-3.19 M | $ 0.51 | 2.18 % | $ 2.19 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
-1.41 M | $ 6.38 | 10.0 % | $ 94.8 M | ||
|
Harrow Health
HROW
|
-5.14 M | $ 32.2 | 9.08 % | $ 1.18 B | ||
|
Pacira BioSciences
PCRX
|
7 M | $ 36.48 | 0.05 % | $ 1.63 B | ||
|
Emergent BioSolutions
EBS
|
52.6 M | $ 5.5 | -1.96 % | $ 294 M | ||
|
Cronos Group
CRON
|
-2.9 M | $ 3.17 | -0.63 % | $ 1.22 B | ||
|
Evolus
EOLS
|
-51.6 M | $ 7.07 | 5.61 % | $ 456 M | ||
|
Organogenesis Holdings
ORGO
|
37 M | $ 0.85 | 4.57 % | $ 108 M | ||
|
Rockwell Medical
RMTI
|
-5.31 M | $ 6.32 | -4.38 % | $ 227 M | ||
|
Bausch Health Companies
BHC
|
157 M | $ 8.74 | 3.13 % | $ 3.24 B | ||
|
OrganiGram Holdings
OGI
|
-45.4 M | $ 0.68 | -4.46 % | $ 64.8 M | ||
|
Perrigo Company plc
PRGO
|
-1.43 B | $ 16.98 | 7.71 % | $ 2.35 B | ||
|
SCYNEXIS
SCYX
|
-8.61 M | $ 2.81 | -1.4 % | $ 140 M | ||
|
Veru
VERU
|
-22.7 M | $ 2.3 | 7.48 % | $ 33.7 M | ||
|
HEXO Corp.
HEXO
|
-1.07 B | - | 2.45 % | $ 38.1 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
-466 M | - | -0.1 % | $ 2.03 B | ||
|
Viatris
VTRS
|
-3.51 B | $ 20.27 | -0.86 % | $ 23.2 B | ||
|
Sundial Growers
SNDL
|
-15.8 M | $ 1.35 | 0.37 % | $ 348 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
3.18 K | $ 0.82 | -1.81 % | $ 1.38 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
-14.3 M | - | 7.5 % | $ 6.35 M | ||
|
Assertio Holdings
ASRT
|
-30.4 M | - | - | $ 150 M | ||
|
Jupiter Wellness
JUPW
|
-68.2 M | - | - | $ 33.6 M | ||
|
ProPhase Labs
PRPH
|
-14.7 M | - | - | $ 5.07 M |